The ASCENT project is beyond exited to join the Union World Conference 2022 starting tomorrow, and presents several oral abstracts, symposia and e-posters.
ASCENT releases the ‘The Role of Digital Platforms in Medication Adherence’ to provide insight in platforms used for digital adherence technologies
This report, written by consortium partner PATH, captures the current state of the digital platform market.
Chidi Egwuatu from Nigeria wasn’t able to play football or sit in a vehicle for longer than 30 minutes before he started his tuberculosis treatment. He says: “The video helps me, it reminds me to take my medication on time”.
The ASCENT project is pleased the WHO provided this guidance, since it has been our aim from the start to generate pragmatic evidence that DATs can empower TB-patients during their treatment.
The Unitaid-funded ASCENT project has entered its final year and is well on its way in showing the benefits in helping people affected by TB with their treatment by using digital adherence technology such as smart pill boxes, medication sleeves and video supported treatment.
As part of the ASCENT project, funded by Unitaid, PATH and KNCV Tuberculosis Foundation (KNCV) release a suite of resources to expand the market for digital adherence technologies (DATs).
The 52nd edition of the world’s largest lung health gathering took place online. With this year’s theme ‘Lung Health for All: Solutions for a New Era’, the ASCENT project naturally made a contribution.
Devex interview about digital adherence technologies: “We hope that our research will contribute to the WHO policy”
Over the years, digital technologies have been introduced to improve patients’ adherence to tuberculosis (TB) treatment, but with little research showing how feasible these technologies are.
Research begins into new digital tools to support patients and healthcare workers through tuberculosis treatment
A large global study which aims to determine if digital adherence technologies can provide more patient-friendly approaches to improve tuberculosis (TB) treatment outcomes launches in Ethiopia, Tanzania, South Africa, the Philippines and Ukraine, as part of the ASCENT project.
As the main research phase of the innovative ASCENT project kicks off, we asked the main researchers Jens Levy, Katherine Fielding and Amare Tadesse to elaborate on the study. Why are they so determined to generate scientific evidence on the use of digital adherence technologies for tuberculosis (TB) treatment?